Adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet and longitudinal changes in global cognition: a post hoc analysis of the MIND trial.

Am J Clin NutrJul 15, 2026 (epub)
Clinical ResearchGeriatricsNeurology

Klodian Dhana, Neelum T Aggarwal, Jennifer Ventrelle et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of the MIND trial evaluated the relationship between adherence to the MIND diet and changes in global cognition among 590 community-dwelling adults aged 65 to 84. Participants with substantial improvement in MIND diet scores showed a significant annual increase in global cognitive scores (β = 0.035; 95% CI: 0.006, 0.064) compared to those with no improvement.

Key findings

  • 19.7% of participants showed no improvement in MIND diet score.
  • 42.3% of participants demonstrated substantial improvement in MIND diet score.
  • Greater adherence to the MIND diet was associated with a significant increase in global cognitive scores.
  • Higher plasma lutein-zeaxanthin and β-carotene levels were linked to better adherence.

Why it matters

Understanding the impact of dietary adherence on cognitive function can inform strategies to promote brain health in older adults. Improved adherence to the MIND diet may be a viable approach to enhance cognitive outcomes.

Source

PubMed · PMID 42457038

Published in Am J Clin Nutr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.